Study characteristics
| Acronym (year) | Participants (n, age, sex) | Comorbidity | Intervention/control | Baseline SBP/DBP (mm Hg) | SBP/DBP difference (mm Hg) |
| ACTION (2004) | 7665 63 years 21% female | 100% CAD 14% DM | Nifedipine 60 mg versus placebo | 137.5/79.8 | 5.7/3.0 |
| ACTIVE I (2011) | 9016 70 years 29% female | 36% CAD 20% DM 100% AF | Irbesartan 300 mg versus placebo | 138.3/82.4 | 2.9/1.9 |
| ALTITUDE (2012) | 8561 64 years 32% female | 26% CAD 100% DM 98% CKD | Aliskiren 300 mg versus placebo | 137.3/74.2 | 1.3/0.6 |
| BCAPS (2001) | 793 62 years 55% female | 4% CAD 3% DM All had carotid plaques | Metoprolol CR/XL 25 mg versus placebo | 138.9/84.7 | 1.3/ - |
| DREAM (2006) | 5269 55 years 59% female | 0% CAD 0% DM All had IGT/IFG | Ramipril 15 mg versus placebo | 136/83.4 | 4.3/2.7 |
| EUROPA (2003) | 12 218 60 years 15% female | 100% CAD 12% DM | Perindopril 8 mg versus placebo | 137/82 | 5/2 |
| HOPE (2000) | 9297 66 years 27% female | 81% CAD 38% DM | Ramipril 10 mg versus placebo | 139/79 | 3/2* |
| HOPE-3 (2016) | 12 705 66 years 46% female | 0% CAD 6% DM | Candesartan/HCTZ 16/12.5 mg versus placebo | 138.1/81.9 | 6/3 |
| Lewis (1993) | 409 35 years 47% female | 100 % DM (type 1) All with nephropathy | Captopril 75 mg versus placebo | 138.5/85.5 | 1.5/2.5 |
| NAVIGATOR (2010) | 9306 64 years 51% female | 24% CAD 0% DM 100% IGT | Valsartan 160 mg versus placebo | 139.7/82.6 | 2.8/1.4 |
| PART-2 (2000) | 617 61 years 18% female | 68% CAD (100% CVD) 9% DM | Ramipril 5–10 mg versus placebo | 133/79 | 5.5/4 |
| PEACE (2004) | 8290 64 years 18% female | 100% CAD 17 % DM | Trandolapril 4 mg versus placebo | 133/78 | 3.0/1.2 |
| PHARAO (2008) | 1008 62 years 52% female | 6% CAD 13% DM | Ramipril 5 mg versus placebo | 134.4/83.6 | 2.8/0.9 |
| PREVEND-IT (2004) | 864 51 years 35% female | 3% CAD 3% DM | Fosinopril 20 mg versus placebo | 130/76 | 3/3 |
| Ravid (1998) | 194 55 years 51% female | 0% CAD 100% DM | Enalapril 10 mg versus placebo | MAP 97 | -/ - |
| ROADMAP (2011) | 4447 58 years 54% female | 25% CAD 100% DM | Olmesartan 40 mg versus placebo | 136.5/80.5 | 3.1/1.9 |
| SCAT (2000) | 460 61 years 11% female | 100% CAD 11% DM | Enalapril 10 mg versus placebo | 130/77.5 | 5.2/3.3 |
| VA-NEPHRON (2013) | 1448 65 years 0.3% female | 23% CAD 100% DM with nephropathy | Losartan/lisinopril 100/10–40 mg versus losartan 100 mg | 137.0/72.7 | 1.5/1.0 |
*A substudy assessing ABPM found larger BP differences between groups during follow-up, indicating potentially underestimated BP differences in the main publication.
ABPM, ambulatory blood pressure measurement; AF, atrial fibrillation;BP, blood pressure; CAD, coronary artery disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; DM, diabetes mellitus; HCTZ, hydrochlorothiazide;HOPE3, third Heart Outcomes Prevention Evaluation; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; MAP, mean arterial pressure; SBP, systolic blood pressure.